> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# BillionToOne Lifts 2026 Revenue Forecast To $460 Million-$470 Million As Oncology Sales Rise 96%
- URL: https://www.bullished.co/billiontoone-lifts-2026-revenue-forecast-to-460-million-470-million-as-oncology-sales-rise-15df0286/
- Published: 2026-11-04T23:56:11.000Z
- Updated: 2026-11-04T23:56:11.000Z
- Description: The diagnostics company reported third-quarter revenue up 47% and plans to launch a blood-only cancer monitoring test on December 15.
- Author: Matteo Parrino
- Tags: Earnings, BLLN, Industry: Healthcare

BillionToOne, which makes blood tests for prenatal screening and cancer care, raised its 2026 revenue forecast to [$460 million to $470 million](https://www.sec.gov/Archives/edgar/data/0002070849/000207084926000078/a991blln-earningspressrele.htm?ref=bullished.co) after third-quarter sales climbed 47% to $123.0 million. The company said Wednesday that oncology revenue nearly doubled and that a new blood-only cancer test goes on sale next month.

## Volume and price both rose

Third-quarter revenue of $123.0 million compares with $83.5 million a year earlier. Tests delivered rose 25% to 206,000, and average revenue per test rose 18% to $589, the company reported in an [8-K](https://www.sec.gov/Archives/edgar/data/0002070849/000207084926000078/blln-20261104.htm?ref=bullished.co) filed Wednesday.

Prenatal testing brought in [$104.3 million](https://www.globenewswire.com/news-release/2026/11/04/3395817/0/en/billiontoone-reports-third-quarter-2026-results-and-raises-2026-revenue-guidance.html?ref=bullished.co), up 41%. Oncology revenue was $17.1 million, 96% above the $8.7 million of a year earlier. For the first nine months, total revenue was $340.8 million, up 63%, with oncology up 162%.

The new full-year range, which the company says represents 51% to 54% growth over 2025, replaces a prior range of $450 million to $465 million. Management also said it expects to keep generating profitability similar to current levels despite significant continued investment.

## Profit up, spending up faster

Net income was [$17.4 million](https://wtop.com/national/2026/11/billiontoone-q3-earnings-snapshot/?ref=bullished.co), or $0.32 per diluted share. The year-earlier comparison is $1.5 million, or $0.10 per diluted share, which is net income attributable to common stockholders; total net income then was $5.7 million. Operating income was $11.0 million against $9.6 million.

Operating expenses rose 56% to $76.1 million, faster than revenue. Gross margin edged up to 71% from 70%. Cost per test rose slightly, which the company attributed to faster growth in oncology products, which cost more per test.

Free cash flow, operating cash flow minus capital spending, was [$8.6 million](https://www.globenewswire.com/news-release/2026/11/04/3395817/0/en/billiontoone-reports-third-quarter-2026-results-and-raises-2026-revenue-guidance.html?ref=bullished.co). Cash stood at $561.5 million on September 30, up from $496.0 million at the end of 2025.

## A blood-only test due December 15

BillionToOne's UNITY prenatal screens and Northstar cancer tests run on a platform that counts individual DNA molecules in blood. Its new product, Northstar Clear, is a tissue-free test for detecting residual cancer in patients with any solid tumor. It becomes commercially available on December 15, 2026, and initial colorectal cancer data will show head-to-head performance against a tumor-informed assay, the company said.

CEO Oguzhan Atay said the company is "still in the early chapters of what our platform can achieve." The company also cited an October study in which Northstar Response and a widely used tumor-informed test agreed on the direction of tumor DNA change in 67 of 71 sequential pairs.

Northstar Clear reaches the market on December 15, 2026, the next dated event the company has set.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — BillionToOne, Inc. (BLLN)](https://www.sec.gov/Archives/edgar/data/0002070849/000207084926000078/blln-20261104.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit a991blln-earningspressrele.htm — BillionToOne, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0002070849/000207084926000078/a991blln-earningspressrele.htm?ref=bullished.co) — SEC EDGAR
- [BillionToOne: Q3 Earnings Snapshot – WTOP News](https://wtop.com/national/2026/11/billiontoone-q3-earnings-snapshot/?ref=bullished.co) — wtop.com
- [BillionToOne: Q3 Earnings Snapshot | kare11.com](https://www.kare11.com/article/syndication/associatedpress/billiontoone-q3-earnings-snapshot/616-a850692d-b397-4ea1-8fb5-e93385f2846d?ref=bullished.co) — Associated Press
- [BillionToOne Reports Third Quarter 2026 Results and Raises](https://www.globenewswire.com/news-release/2026/11/04/3395817/0/en/billiontoone-reports-third-quarter-2026-results-and-raises-2026-revenue-guidance.html?ref=bullished.co) — globenewswire.com